Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment

Altimmune ((ALT)) announced an update on their ongoing clinical study.

Study Overview: The RESTORE TRIAL is a Phase 2 study conducted by Altimmune, Inc., aimed at evaluating the efficacy and safety of pemvidutide in treating Alcohol-Associated Liver Disease (ALD). This multicenter, randomized, double-blind, placebo-controlled study seeks to provide significant insights into potential treatments for ALD, a condition with limited therapeutic options.

Intervention/Treatment: The study tests pemvidutide, administered as a 2.4 mg subcutaneous injection once weekly, against a placebo. Pemvidutide is designed to assess its effectiveness in improving liver health in patients with ALD.

Study Design: Participants are randomly assigned to either the pemvidutide group or the placebo group, with both participants and researchers blinded to the assignments. The study follows a parallel intervention model, focusing primarily on treatment outcomes.

Study Timeline: The study began on June 5, 2025, with the latest update submitted on July 8, 2025. These dates mark the commencement of participant recruitment and the most recent progress update, respectively, indicating the study’s active status.

Market Implications: This study update could influence Altimmune’s stock performance positively, as successful results may enhance investor confidence and position the company as a leader in ALD treatment. Competitors in the liver disease treatment market may also respond to these developments, potentially affecting industry dynamics.

The RESTORE TRIAL is currently ongoing, with further details available on the ClinicalTrials portal.